earnings
confidence high
sentiment neutral
materiality 0.65
TriSalus Q1 rev $9.2M (+42% YoY); revises 2025 guidance: 50% growth, no adj. EBITDA positive
TriSalus Life Sciences, Inc.
2025-Q1 EPS reported
-$0.39
revenue$9,167,000
- Net sales $9.2M, up 42% YoY and 11% sequential; gross margin 84% vs 85%.
- Net loss available to common $10.4M ($0.39 diluted loss per share) vs $13.2M ($0.60) prior year.
- Adjusted EBITDA loss narrowed to $5.5M from $10.4M; cash $13.0M at Mar 31, then raised $22M via private placement.
- 2025 guidance: confirms 50% rev growth; no longer expects adj. EBITDA or cash flow positive in 2025.
- Agreement with 55% of preferred shareholders to simplify capital structure; preferred conversion by mid-July 2025.